Compare · SLNO vs STEX
SLNO vs STEX
Side-by-side comparison of Soleno Therapeutics Inc. (SLNO) and Streamex Corp. (STEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLNO and STEX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 31.0x STEX ($89.1M).
- Over the past year, SLNO is down 20.3% and STEX is down 85.5% - SLNO leads by 65.2 points.
- STEX has been more active in the news (7 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 1 for STEX).
- Company
- Soleno Therapeutics Inc.
- Streamex Corp.
- Price
- $53.02+0.08%
- $0.77-6.76%
- Market cap
- $2.76B
- $89.1M
- 1M return
- +0.76%
- +4.77%
- 1Y return
- -20.28%
- -85.49%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 1
- 7
- Recent ratings
- 12
- 1
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest STEX
- Streamex Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Streamex to Participate as Innovator Partner at the Real-World Asset Summit in Brooklyn, New York; CEO Henry McPhie to Join Panel on Commodities Tokenization on September 2, 2026
- Siebert Partners with tZERO to Give Access to Digital Securities to Its Customers
- Streamex Corp. Announces July 2026 Yield Dividend Distribution for GLDY
- Streamex Corp. Reports Second Quarter 2026 Financial Results
- Streamex Corp. filed SEC Form 8-K: Leadership Update
- Streamex Corp. to Report Second Quarter 2026 Results and Host Business & Corporate Update Call
- Streamex Corp. Releases Investor Video on the Platform Strategy and Growth Initiatives Featuring VP of Product and Design Kori Handy
- Streamex Corp. Details GLDY’s Liquidity Infrastructure; ~$12 Million in Seeded Liquidity Supports 24/7, 365 Instant Trading Across Multiple Institutional-Grade Venues
- Streamex Corp. Announces 24/7, 365 Instant Liquidity for GLDY Through Collaboration with Wintermute